The alarmingly increasing resistance rates among non-fermenting Gram-negative species, particularly Pseudomonas aeruginosa and Acinetobacter baumannii, intensified the interest in alternative
antibiotic treatment options.
Isepamicin, an old
aminoglycoside, may play a role in the treatment of patients with
infections caused by those multi-
drug resistant pathogens. We evaluated the antimicrobial activity of
isepamicin against non-fermenting Gram-negative isolates collected of the microbiological laboratory at the University Hospital of Heraklion, Crete, Greece from 2004 to the first trimester of 2011. We tested a total of 4,219 isolates (66.2 % Pseudomonas spp., 30 % Acinetobacter spp., 3.8 % other non-fermenters). The lower respiratory tract,
pus, and urine were the most frequent sites of isolation (29.7 %, 19.9 %, and 12.9 %, respectively). Overall, 2768 (65.6 %) of the evaluated isolates were susceptible to
isepamicin (including 79.9 % of Pseudomonas spp, 37.2 % of Acinetobacter spp, 43.1 % of other non-fermenters).
Isepamicin exhibited higher antimicrobial activity compared to broad spectrum
penicillins,
cephalosporins, other
aminoglycosides,
carbapenems, and
fluoroquinolones. Only
colistin was more active than
isepamicin. Additionally, 41.7 % of
carbapenem-resistant and 53.2 % of
colistin-resistant P. aeruginosa isolates were susceptible to
isepamicin. The susceptibility rates for the respective types of A. baumannii isolates were 12 % and 6.2 %. Yet,
isepamicin was active against 29.2 % of A. baumannii that were resistant to all other tested
aminoglycosides.
Isepamicin exhibits considerable antimicrobial activity against Gram-negative non-fermenters in a region with high antimicrobial resistance. Particularly,
isepamicin may provide a therapeutic option for
infections from
carbapenem- and
colistin-resistant P. aeruginosa and other
aminoglycoside-resistant A. baumannii. Further modifications in the
aminoglycoside molecule may provide formulations with enhanced antimicrobial activity.